Protein Kinase A in Complex with Rho-Kinase Inhibitors Y-27632, Fasudil, and H-1152P Structural Basis of Selectivity by Breitenlechner, Christine et al.
Structure, Vol. 11, 1595–1607, December, 2003, 2003 Elsevier Science Ltd. All rights reserved. DOI 10.1016/j .str .2003.11.002
Protein Kinase A in Complex with Rho-Kinase
Inhibitors Y-27632, Fasudil, and H-1152P:
Structural Basis of Selectivity
processes such as cell survival or cell migration. The
prevalence of kinases to cause or augment disease un-
derscores the need for therapeutic protein kinase inhibi-
tors, with the caveat that they must be highly selective
for their disregulated targets to avoid inhibition of other
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69120 Heidelberg for the treatment of cerebral vasospasm, a painful and
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Fasudil’s activity has been attributed to inhibition of4 D-Western Therapeutics Institute
Yagota Building 2C Rho-kinase (Matsui et al., 1996) and its role in signaling
for myosin light chain phosphorylation and arterial100-32 Yagotohonmachi
Showa-ku, Nagoya 466 0825 smooth muscle contraction (Amano et al., 1996), al-
though the in vitro activity of fasudil is not strictly limitedJapan
to Rho-kinase. Other Rho-kinase-related protein ki-
nases, such as PKA, PRK2, MSK1, and S6K1, are also
inhibited by fasudil, although to a lesser extent (DaviesSummary
et al., 2000). Fasudil is related to H7, an isoquinoline
sulfonamide derivative that is a weak PKC inhibitor (Hi-Protein kinases require strict inactivation to prevent
spurious cellular signaling; overactivity can cause can- daka et al., 1984) and whose protein kinase binding
mode was shown by the cocrystal structure with PKAcer or other diseases and necessitates selective inhi-
bition for therapy. Rho-kinase is involved in such pro- (Engh et al., 1996). Fasudil has a heptameric homopiper-
azine ring at the position of the methyl-piperazine ringcesses as tumor invasion, cell adhesion, smooth
muscle contraction, and formation of focal adhesion of H7 (Figure 1). Further derivitization of fasudil led to
H-1152P, with two additional methyl groups, one at thefibers, as revealed using inhibitor Y-27632. Another
Rho-kinase inhibitor, HA-1077 or Fasudil, is currently isoquinoline ring and the other at the homopiperazine
ring (Tanaka et al., 1998). H-1152P has a better inhibitoryused in the treatment of cerebral vasospasm; the re-
lated nanomolar inhibitor H-1152P improves on its se- profile than HA-1077, with a KD value for Rho-kinase in
the low nanomolar range and a reportedly enhancedlectivity and potency. We have determined the crystal
structures of HA-1077, H-1152P, and Y-27632 in com- selectivity (Tanaka et al., 1998; Sasaki et al., 2002). Rho-
kinase may be an important pharmacological target alsoplexes with protein kinase A (PKA) as a surrogate kinase
to analyze Rho-kinase inhibitor binding properties. for cancer because of its role in the phosphorylation of
focal adhesion kinase (Sinnett-Smith et al., 2001) andFeatures conserved between PKA and Rho-kinase are
involved in the key binding interactions, while a combi- the invasion and migration of cancer cells (for reviews,
see Fukata et al., 2001; Amano et al., 2000). Regardingnation of residues at the ATP binding pocket that are
unique to Rho-kinase may explain the inhibitors’ Rho- the latter, Itoh et al. (1999) showed that the migration
of rat MM1 hepatoma cells was prevented by the Rho-kinase selectivity. Further, a second H-1152P binding
site potentially points toward PKA regulatory domain kinase inhibitor Y-27632. As a pyridine derivative,
Y-27632 differs in its chemical structure from H inhibitorsinteraction modulators.
described above. It has a KD of 140 nM for Rho-kinase
and 25 M for PKA (Ishizaki et al., 2000) and is ATPIntroduction
competitive, like the H inhibitors (Trauger et al., 2002;
Ikenoya et al., 2002).Protein kinases are phosphorylation enzymes that con-
Crystal structure analyses of protein kinase inhibitortrol cellular signaling events and accordingly may cause
complexes reveal the intermolecular interactions re-a wide range of diseases when defective. Since they
sponsible for ligand binding and thereby enable struc-are typically active only when signaling, most of the
ture-based rational design and optimization of kinasediseases associated with protein kinase deregulation
inhibitors. To date, crystal structures have been deter-(including the majority of all cancers) arise from excess
mined for some 30 protein kinases, representing lessactivity due to mutation, overexpression, or disabled
than 6% of the 518 protein kinases in the human genomecellular inhibition. Other protein kinases contribute to
(Manning et al., 2002). Many of these structures havedisease in the course of their normal function in cellular
been complexes with protein kinase inhibitors, but most
have shown an inactive state. As a serine-threonine ki-*Correspondence: d.bossemeyer@dkfz.de (D.B.), engh@biochem.
mpg.de (R.A.E.) nase of the AGC group, Rho-kinase possesses a cata-
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analyze the factors governing their relative affinities for
PKA and Rho-kinase. The structures identify the binding
interactions of the inhibitors in the ATP pocket. The
surface areas of the inhibitor/PKA interface correlate
well with their inhibitory activities. Furthermore, the spe-
cific sequence differences between PKA and Rho-
kinase provide an explanation for the observed higher
affinity of these molecules for Rho-kinase. On the basis
of these structural data, we propose models for the Rho-
kinase-specific binding modes that rationalize the roles
of the unique combination of amino acid residues found
in the Rho-kinase ATP binding pocket. In addition, a
second, well ordered H-1152P molecule was observed
in a surface region with contact to the phosphoryl group
of Thr197 and to Lys189, both from the activation loop,
and to Glu86 from Helix C, a region critical for kinase
activity and protein-protein interaction.
Results and Discussion
Overall Structure
The PKA complexes with Rho-kinase inhibitors Y-27632
(PKA-Y), fasudil or HA-1077 (PKA-1077), and H-1152P
(PKA-1152) were cocrystallized as ternary complexes
with the recombinant catalytic subunit of cyclic AMP-
dependent protein kinase (PKA) and the pseudo-sub-
strate kinase inhibitor peptide [PKI(5-24)]. All three inhib-
itor complexes crystallized in the orthorhombic space
group P212121. The PKA-1152 and PKA-Y crystals haveFigure 1. Chemical Structures of the Inhibitors Y-27632, HA-1077,
and H-1152P similar cell constants (ca. 74.1, 76.6, 81.0) and the same
crystal packing arrangement (Table 1). PKA-1077 has
slightly different cell constants (70.33, 73.67, 79.08) and
lytic domain closely related to other AGC group kinases, different crystal contacts. The inhibitor molecules oc-
among them PKA, PKB, PKC, and PKG, although no cupy the ATP binding site; H-1152P binds additionally
crystal structure of Rho-kinase has been reported. The at a second site bounded by pThr197, helix C residues,
close relationship between PKA and Rho-kinase and the and residues from the PKI(5-24) peptide of a symmetry
well established crystallization conditions for PKA make related molecule. Apart from that, no direct contacts
PKA a suitable model system for studying Rho-kinase exist between any of the inhibitors and PKI(5-24).
inhibitors. Furthermore, cocrystallization of PKA with
Rho-kinase inhibitors helps identify factors governing Open and Closed Conformations
cross selectivity of protein kinase inhibitors, a major Ligand-induced conformational changes have been well
concern in protein kinase inhibitor design. documented for PKA (Prade et al., 1997; Johnson et
The ATP binding site residues conserved between al., 2001). Foremost among these are variations in the
PKA and Rho-kinase include Phe327 (PKA numbering). relative orientations of N- and C-terminal lobes, whose
This residue is a characteristic but not absolutely con- interface creates the ATP binding pocket. The “open-
served feature of the AGC group of kinases. It is posi- ness” of the pocket ranges from “closed” for PKA struc-
tioned on the C-terminal polypeptide strand which tures with bound ATP or AMPPNP (PDB code 1ATP,
stretches between the  helical catalytic domain lobe 1CDK) in the presence of pseudosubstrate, “closed”
and the C-terminal anchor in the hydrophobic motif. or “intermediate” for various inhibitors, to “open” for
Phe327 shields one side of the ATP pocket and lies unliganded PKA (PDB code 1J3H; Akamine et al., 2003).
adjacent to the adenine of ATP and aromatic groups of The extent of openness can be quantitatively character-
ATP-site inhibitors (Prade et al., 1997; Engh et al., 1996). ized by using several parameters. One is the occurrence
Rho-kinase and PKA differ, however, in eight positions of a hydrogen bonding distance between NE2 of His87
in the ATP binding pocket (Figure 2). Four of their side from helix C and pThr197 (O3P) of the activation loop
chains are in close (4 A˚) contact with the inhibitors, in the closed conformation. By this measure, the struc-
corresponding to the following PKA→Rho substitutions: tures of PKA-Y and PKA-1152 (Figure 3, green ribbon,
Leu49Ile, Val123Met, Thr183Ala, and Glu127Asp. Be- 2.5 A˚; yellow ribbon, 2.6 A˚) represent closed lobe struc-
cause the protein kinase fold is so highly conserved, tures, whereas the PKA-1077 structure is—with a 4.6 A˚
variations of amino acid residues that line the ATP sub- separation—an open structure (Figure 3, red ribbon).
site belong to the most important factors in defining
inhibitor selectivity. Here we describe the crystal struc- Glycine Loop
tures of PKA in complex with HA-1077 (at 2.2 A˚ resolu- The flexibility of the glycine loop is demonstrated by
relatively high B factors and by the occurrence of dif-tion), with H-1152P (1.9 A˚), and with Y-27632 (2.0 A˚) and
Crystal Structures of PKA with Rho-Kinase Inhibitors
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Figure 2. Sequence Alignment of PKA and the Highly Similar Rho Kinase Family Members ROCK-I and ROCK-II
Blue backgrounds indicate identical residues whereas brown indicates conservative exchanges. Secondary structure elements of PKA (from
Bossemeyer et al., 1993) are indicated above the PKA numbering. The most highly conserved kinase residues are shown in red letters. Inhibitor
contacts are marked with light violet letters and boxes. Additionally, contacts with H-1152P in the second binding site are indicated in green.
ferent positions in all three structures. The differing PKI(5-24)/MnAMP-PNP) (Bossemeyer et al., 1993), PKA-Y,
PKA-1152, and PKA-1077 (3, 4) (Figure 3C, blue, green,positions create ATP ligand binding sites that are pro-
gressively more open among structures 1CDK (PKA/ yellow, and red ribbon, respectively). There is also evi-
Table 1. Data Collection and Refinement Statistics
Y-27632 H-1152P HA-1077
Data Collection
Space group P212121 P212121 P212121
Cell (a, b, c) (A˚) 74.0, 76.6, 80.7 74.2, 76.4, 81.8 70.3, 73.7, 79.1
Resolution range (A˚) 15.8–2.0 10.91–1.9 20–2.2
Completeness (%) [last shell] 97.8 [88.7] 91.8 [56.0] 82.4 [59]
I/(I) [last shell] 4.2 [1.4] 7.5 [0.6] 7.5 [1.3]
Rsym [last shell] 0.12 [0.50] 0.06 [0.51] 0.10 [0.34]
Refinement
Number of atoms used in refinement 3104 3245 2914
R factor (%) 18.1 17.9 21.7
Free R factor (%) 22.9 21.7 29.3
Free R value test size (%) 10.1 5.0 5.0
Reflections used 27,774 32,327 16,761
Standard Deviation from Ideal Values
Bond length (A˚) 0.016 0.017 0.021
Bond angles () 1.440 1.491 1.83
Temperature Factors
All atoms 39.4 25.1 24.4
Main chain/side chain atoms PKA 37.6/40.0 22.9/25.5 23.1/25.2
Main chain/side chain atoms PKI 32.8/36.7 21.0/23.9 26.6/29.8
Inhibitor atoms 38.3 33.3 23.2
Solvent molecules 50.3 36.6 25.8




Figure 3. Binding of the Inhibitors to PKA
(A) Open-closed conformations illustrated by an overlay of all three inhibitor structures (Y-27632, green; HA-1077, red; H-1152P, yellow) and
the PKA-AMP-PNP (1CDK) complex (blue) for comparison.
(B) In the PKA-HA1077 structure, helix C is further away from the activation loop, and the salt bridge His87-pThr197 is not formed.
(C) A closer view of the binding pocket shows the inhibitor binding modes relative to AMP-PNP and the positions of the flexible glycine-loop.
The inhibitor molecules occupy both the adenine and the ribose pocket, but not the triphosphate binding site.
dence for multiple conformations of the glycine flap turn residues Ser53-Phe54-Gly55), similar to that pre-
viously observed with the H7 and H8 inhibitor complexwithin a single crystal (data not shown). PKA-Y electron
density maps suggest the partial occupancy of a more structures of PKA (Engh et al., 1996). Because none of
the cocrystallized inhibitors occupies this site, they doclosed position of the glycine flap (especially involving
Crystal Structures of PKA with Rho-Kinase Inhibitors
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not have the structuring effect of the triphosphoryl group binding pocket, especially to the invariable Val57 with
9 or 10 side chain contacts and to the more variableof ATP with its contacts to the glycine loop.
Val123 with 12 contacts. Four contacts are formed to
Phe327, the residue characteristic of the AGC kinasesInhibitor Binding
that is inserted into the ATP pocket from the C-terminalThe chemical structures of the three inhibitors are shown
strand of the kinase. The two conformations differ mostin Figure 1. They originate from two different chemical
at the terminal aminoethyl group, which adopts eitherclasses but share the general architecture of a planar
one H bond between N17 and the backbone carbonylring system linked to a saturated ring. In the case of
oxygen of Thr51 (2.83 A˚) (Table 4; Figure 5A), or a HY-27632, a pyridine ring is connected by an amide to a
bond with Asn171 (OD1) (2.89 A˚) and Asp184 (OD1)saturated para-aminoethyl cyclohexane ring. HA-1077
(2.93 A˚) (Table 4). The pyridine ring in both conformationsand its derivative H-1152P share the basic scaffold of
forms a H bond between pyridine nitrogen atom N1 andan isoquinoline ring connected to a homopiperazine ring
backbone nitrogen of Val123 (2.93 A˚) (Figure 5A), theby a sulfonamide linker. Compared to HA-1077, H-1152P
hydrogen bond donor at the hinge region between thehas two additional methyl groups, one at the isoquino-
N- and C lobes that binds to nearly all known ATP-siteline ring and another at the homopiperazine ring. These
inhibitors (Engh and Bossemeyer, 2001). Y-27632 alsotwo methyl groups are thus responsible for the unique
binds via water molecules sandwiched between N7 andbinding properties of the derivative. The planar ring sys-
the carboxylate of Glu127 and the backbone carbonyltems occupy the adenine subsite, while the linker and
of Leu49.the saturated rings occupy the ribosyl subsite. The tri-
phosphate subsite is not used by any of the inhibitors
(Figures 3C and 4). HA-1077
As described in the introduction, HA-1077, also knownFigure 4 shows the inhibitors in the ATP pocket and
the Fo-Fc electron density maps with the inhibitor atoms as fasudil, is used to treat cerebral vasospasm and
works via Rho-kinase inhibition. However, it also inhibitsomitted contoured at 2.5. Y-27632 is well defined in
the electron density (Figure 4A), which, however, does several other kinases in the M range (Davies et al.,
2000). Our SPR data show a KD value of 5.7 M for PKA;not uniquely identify the orientation of the cyclohexane
ring chair conformer (see next paragraph). The typical published data include a Ki value of 1.0 M (Ikenoya et
al., 2002) (Table 2). HA-1077 makes three H bonds tointrinsic flexibility of the seven-membered homopipera-
zine rings of HA-1077 and H-1152P is reflected in less PKA (Figure 5B; Table 4). Like other isoquinoline inhibi-
tors (Engh et al., 1996), one H bond is formed betweenwell defined electron densities in this region (Figures 4B
and 4C). The electron density of H-1152P (Figure 4C) the isoquinoline N (N15) to the backbone N of Val123
(2.8 A˚). The homopiperazine amine (N4) forms H bondshas gaps in portions of the homopiperazine ring too,
contradicting expectations that the two extra methyl with the backbone carbonyl oxygen of Glu170 (3.25 A˚)
and the side chain of Glu127 (OE2) (2.69 A˚), the lattergroups should stabilize the ring conformations relative
to HA-1077. In contrast, the homopiperazine ring of at the position of the ribose 3OH group in the ATP-PKA
complex (Bossemeyer et al., 1993). A Glu127-inhibitorthe H-1152P inhibitor bound outside the catalytic cleft
close to Thr197 of the activation loop binds with a clearly contact was observed for staurosporine (Prade et al.,
1997), but not with the other isoquinoline sulfonamidedefined electron density for the whole inhibitor (Fig-
ure 4D). inhibitors (Engh et al., 1996). A total of 81 van der Waals
contacts are formed to the residues of the ATP pocket.
Most contacts are to Val123 (13), Val57 (11), and Thr183Binding of Y-27632
(11) (Table 4).With a KD value of 17.5  3.87 M by surface plasmon
resonance spectroscopy (SPR) and a 25 M Ki value
from previous kinetic data (Uehata et al., 1997), Y-27632 H-1152P
H-1152P is a derivative of HA-1077 with enhanced speci-has the weakest PKA inhibition of the compounds stud-
ied here (Table 2). For Rho-kinase, however, Y-27632 ficity for Rho-kinase (Sasaki et al., 2002). For PKA, it has
a KD (SPR) or Ki (Ikenoya et al., 2002) value of 1.06 orhas a Ki value of 140 nM. This pronounced selectivity
for Rho-kinase is further emphasized by data showing 0.63 M, respectively (Table 2). With a Ki of 1.6 nM,
H-1152P inhibits Rho-kinase potently (Sasaki et al.,that Y-27632 inhibited only one other protein kinase
(PRK2) from a panel of 34 kinases with similar potency 2002; Ikenoya et al., 2002). The H-1152P molecule that
binds to the ATP pocket makes only one H bond contact(Davies et al., 2000).
Despite the relatively weak PKA inhibition, Y-27632 (from the isoquinoline N [N16] to the backbone NH of
Val123 [3.0 A˚]) (Figure 5C; Table 3). As with the othercocrystallized readily and is clearly localized in the elec-
tron density, although two orientations of a chair con- inhibitors described here, Val57 and Val123 are involved
in many van der Waals contacts; in contrast to the otherformer of the cyclohexane ring are possible (Figure 4A).
To analyze the binding of Y-27632 to PKA, we consid- two inhibitors, Leu173 and Leu49 additionally form many
contacts (Leu173: 12 with H-1152P versus 2 with HA-ered binding surfaces and hydrophobic (van der Waals),
and hydrophilic (H bonds) interactions for both confor- 1077; and Leu49: 8 with H-1152P versus 2 with Y-27632
and 4 with HA-1077).mations (see Tables 3–5). The buried surface areas (188
or 189 A˚2) and numbers of van der Waals contacts (64 In its second binding site close to helix C and the
activation segment, H-1152P makes five H bond con-or 67) are similar for the two conformations. The van
der Waals contacts are formed to residues from the ATP tacts, three to the Thr197-phosphoryl group in the acti-
Structure
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Figure 4. Structure of Inhibitor Binding Sites with Electron Density Maps
Shown are the three PKA bound inhibitors with corresponding Fo-Fc electron density maps (inhibitor atoms omitted) contoured at 2.5. Amino
acid residues in the vicinity of the inhibitors are shown. H bonds between inhibitor atoms and enzyme residues are depicted as dotted lines.
The PKA-PKI-AMP-PNP complex is drawn as fine black lines. Inhibitors (A) Y-27632, (B) HA-1077, and (C) H-1152P bind in the ATP pocket.
(D) The second H-1152P molecule, which occupies a binding site at the enzyme surface in contact with the activation loop and helix C, is
well ordered, indicated by its well defined electron density. (Residues from a symmetry-related molecule are colored yellow.)
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ring, increasing van der Waals contacts and apparentlyTable 2. Inhibitor Binding Properties
enhancing hydrophobic effect binding. A similar reorien-
Inhibitor Y-27632 HA-1077 H-1152P tation of this side chain was observed in the H8-inhibitor
complex of PKA (Engh et al., 1996), where Asp184 makesKD PKA 17.5  3.9 M 5.7  1.2 M 1.1  0.1 M
Ki PKAa 25 M 1.0 M 0.63 M an H bond contact to the amide of the inhibitor side
Ki RHOa 0.14 M 0.33 M 0.0016 M chain. Thr183 and Leu173 in the PKA-Y structure appar-
Buried surface 188(189) 196.4 215.7 ently have two conformations that were each modeled
VDW contacts 64(67) 81 96
with an occupancy of 0.50 (data not shown). These twoH bonds 2(3) 3 1
amino acid residues interact with each other by van der
KD values from surface plasmon resonance spectroscopy (SPR) Waals contacts which limit their degree of conforma-
analysis, Chi2 smaller than five, two independent experiments, Inhi- tional freedom, indicating mutually dependent rotamer
bition constants correlate well with the buried surface and number
conformations and a concerted induced fit movement.of van der Waals (VDW) contacts but not with number of H bonds.
The three inhibitors bind with moderate bindinga Ki values from literature (Ikenoya et al., 2002; Sasaki et al., 2002).
strengths to PKA. Their differing affinities (Table 2) corre-
late with the different numbers of van der Waals contacts
and with the contact surface area between the inhibitors
vation loop, one to Lys189 also of the activation loop, and enzyme residues (buried surface) (Table 2). H-1152P,
and one to Thr5 of PKI(5-24) from a symmetry-related which has the highest affinity for PKA, also has the
molecule (Figure 5D). The inhibitor is embedded in a highest number of van der Waals contacts and the largest
network of water molecules, thus making additional con- buried surface (215.7 A˚2). Y-27632, with the weakest
tacts via water to Asn90 from helix C and Thr195 from PKA binding, has the smallest total number of van der
the activation loop. In this activation loop binding site, Waals contacts and a buried surface area of 189.9 A˚2.
the inhibitor electron density is well connected and veri- A relationship of buried surface areas and affinities of
fies a unique conformation of the homopiperazine ring PKA inhibitors has been noted previously (Engh and
with no apparent disorder (Figure 4D). Significant van Bossemeyer, 2002). The simplest measure of hydrophilic
der Waals contacts are made to the side chain of Glu86 binding interactions—the number of inhibitor-protein H
from helix C, which changes its side chain conformation bonds—does not correlate with PKA binding affinities.
(compared to 1CDK) to accommodate the inhibitor. Fur- This is typical of enzyme inhibitors and reflects the exis-
ther binding studies are necessary to determine the rele- tence of competing hydrophilic interactions in inhibitor
vance of the second binding site in solution. solvation. H-1152P possesses only a single H bond from
its isoquinoline ring to Val123 in the hinge region. This
Binding Specificities of Y-27632, HA-1077, H bond to Val123 or its equivalent is nearly universal
and H-1152P among protein kinase-inhibitor complexes and exists in
Comparison with the Mn2-AMP-PNP complex identifies all PKA-inhibitor complexes crystallized so far (Nara-
only small induced-fit movements of ATP pocket resi- yana et al., 1999; Prade et al., 1997; Engh et al., 1996).
dues associated with binding of the three inhibitors. The Indeed, a survey of ligand binding properties from pro-
side chain of Asp184, which chelates a metal ion in the tein kinase crystal structures in the protein data bank
active complex, is oriented toward the opening of identifies only two inhibitors that lack such an interac-
the active side cleft in the AMP-PNP complex and in tion, namely CK2/Emodin (1F0Q) (Battistutta et al., 2000)
the PKA-Y or PKA-1152 structure. In the PKA-1077 and p38/BPU (1KV1). All other ligands make one, two,
structure, however, Asp184 adopts a different rotamer or three H bonds to the hinge polypeptide, i.e., always
one to the hinge region backbone amide of the Val123(Figure 5B), which points toward the homopiperazine
Table 3. Van der Waals Contacts of the Inhibitors to PKA Enzyme Residues
Residue Y Chair1 Y Chair2 HA-1077 H-1152P Interaction via
L49 2 2 4(1p*) 8(1p*) main chain/side chain
G50 — 1 2 4(1p*) main chain
T51 3 3 — 5 main chain
V57 9 10 11 12 side chain
A70 4 4 6 7 side chain
M120 1 1 4 4 side chain
E121 2(1p*) 2(1p*) 3(1p*) 3(1p*) main chain
Y122 6 6 7 6 main chain/side chain
V123 12 12 13 10(1p*) main chain/side chain
E127 — — 4 4(2p*) side chain
E170 2 2 2 4 main chain
N171 6 4 2 2 main chain/side chain
L173 5 6 2 12 side chain
T183 4(1p*) 6(1p*) 11 7 side chain
D184 4 4 4 — side chain
F327 4 4 6 8 side chain
Total 64(2p*) 67(2p*) 81(2p*) 96(6p*)
Residues that have side chain contacts with the ATP-site ligands and differ between Rho-kinase and PKA are in bold.
Figure 5. Inhibitor Binding Modes
Binding of Y-27632 (A) and HA-1077 (B) to PKA to the ATP binding site. H-1152P binds in two positions: (C) in the ATP binding site and (D)
in a second binding site at the surface interacting with the activation loop and helix C in a crystal contact region.
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Table 4. H Bonds between Inhibitor Atoms and PKA Enzyme Residues
H Bonds Inhibitor Atom PKA Residue and Atom Distance (A˚) Interaction via
Y-27632 chair 1 N1 Val123(N) 2.9 main chain
N17 Thr51(O) 2.8 side chain
Y-27632 chair 2 N1 Val123(N) 2.9 main chain
N17 Glu171(OD1) 2.9 side chain
N17 Asp184(OD1) 2.9 side chain
HA-1077 N15 Val123(N) 2.8 main chain
N4 Glu170(O) 3.3 main chain
N4 Glu127(OE2) 2.7 side chain
H-1152P N16 Val123(N) 3.0 main chain
H bonds between inhibitor and PKA atoms are listed together with the distance (in A˚) and information about main chain or side chain interaction.
homolog, and, in addition, further contacts to the homo- more generally as a docking site for small molecules in
drug design, other important interactions, for examplelogs of the Val123 and/or Glu121 carbonyl atom(s). This
interaction is conserved despite the wide chemical di- cyclin binding to cyclin-dependent kinases, could be
targeted as well.versity of small molecule protein kinase inhibitors. Thus
the interaction is critical for good inhibitors, or con-
versely stated, the kinase is apparently unable to com- Comparison of the Rho-Kinase and PKA
pensate for the desolvation of the Val123NH equivalent Ligand Binding Sites
group if a potential inhibitor lacks the appropriate hydro- Although the three inhibitors bind and inhibit PKA, all
gen bond acceptor. Hydrogen bonds from other resi- of them bind Rho-kinase more tightly than PKA. Because
dues that bind to the adenosine group of ATP appear of the high conservation of the protein kinase fold, espe-
to be of less importance for protein kinase inhibitor bind- cially for closely related kinases, one can assume that
ing. Two H bonds that are formed between the ribosyl the side chains that are nearest to the inhibitor are the
hydroxyl groups of AMP-PNP and the Glu127 carboxyl major determinants of selectivity. The sequence align-
and the Glu170 main chain carbonyl groups have coun- ment of the kinase domains of Rho-kinase and PKA
terparts in the PKA-1077 structure. The presumably dou- (Figure 2) show either conservation (blue coloring) or
bly protonated secondary amine (N4) of HA-1077 forms conservative exchanges (beige coloring) over large parts
hydrogen bonds both to the carboxyl group of Glu127 of the kinase domain. Rho-kinase has several ex-
and to the backbone carbonyl of Glu170. In the case changes relative to PKA, but only four of them make
of H-1152P, these contacts are not formed, because side chain interactions with the inhibitors: Thr183Ala,
contacts between Thr183 and Leu173 of the enzyme Leu49Ile, Val123Met, and Glu127Asp. These exchanges
and homopiperazine methyl group (C10) of the inhibitor very likely are responsible for the effects of the extra
apparently shift the heptamer ring by ca. 1.5 A˚ in com- methyl groups of H-1152P compared to HA-1077 on
parison to HA-1077. Consequently, the distances to specificity toward Rho-kinase. The two methyl groups
E170(O) (4.2 A˚) and E127 (OD1) (3.57 A˚) are too large for lead to a 200-fold higher affinity for Rho-kinase (Table
tight H bonds. The overlay of the two structures in Figure 2), but only a 2- to 5-fold higher affinity for PKA, or in
6 shows the colocalization of the isoquinoline atoms other words, cause a 40- to 100-fold increase in selec-
with respect to the surrounding residues, and the diver- tivity.
gent positions of the homopiperazine rings. Although The residues nearest to the H-1152P methyl groups
H-1152P makes only one hydrogen bond to the enzyme, are Leu49, Leu173, Thr183, and Phe 327, thus involving
the two extra methyl groups increase the number of van directly two of these four PKA to Rho-kinase exchanges,
der Waals interactions (Table 3) and enlarge the buried and one residue (Phe 327) specific for most AGC ki-
surface area, which probably leads to the enhanced nases. The Thr183Ala substitution would provide more
affinity of H-1152 in comparison to HA-1077. room for the C10 methyl group and possibly allow more
rotamer conformations of Leu173. The interactions of
C10 with Thr183 and Leu173 in PKA appear to force theThe Second Binding Site of H-1152P
The second molecule of H-1152P in PKA-1152P is found H-1152P homopiperazine away from its position in the
PKA-1077 structure (Figure 6), presumably at some en-in contact with the activation segment and helix C, the
two structural elements critical for protein kinase inacti- ergy cost. The exchange of Thr183Ala in Rho-kinase
would, however, allow the homopiperazine to retain itsvation (Engh and Bossemeyer, 2001), which suggests a
potential for activity modulation. Because the residues preferred binding orientation. Consequently, H-1152P
might be able to form hydrogen bonds to both thein contact with this second inhibitor molecule are not
conserved between PKA and Rho-kinase, the observed Glu170 homolog and to the aspartyl residue occupying
the Glu127 homologous position in Rho-kinase. Al-second H-1152P binding site likely appears to be unique
for PKA. Further, this site is an important contact region though the side chain of the aspartyl is shorter by one
methylene group, this should not affect its ability tofor protein-protein interaction with the regulatory sub-
units of PKA (Orellana et al., 1993; Gibbs et al., 1992). hydrogen bond a homopiperazine nitrogen in a position
similar to that of HA-1077 in PKA.Occupation of this site with a small molecule derivative
could provide a means to abolish negative regulation of The effect of the Leu49Ile exchange is more difficult
to evaluate because of the number of possible rotamerPKA by the R subunits. If this site could be explored
Structure
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Figure 6. Comparison of HA-1077 and H-1152P
Overlay of HA-1077 and H-1152P demonstrates the colocalization of the isoquinoline atoms with respect to the surrounding residues. Both
inhibitor molecules form an H bond to the backbone amide of Val123 in the hinge region. The position of the homopiperazine rings, however,
diverge by ca. 1.5 A˚. Consequently, H bonds between the homopiperazine nitrogen and Glu127 and Glu170 are formed only in the PKA-1077
complex. The contact between C10 and Thr183, which prevents as a steric clash a HA-1077-like positioning of the H-1152P homopiperazine
ring, is shown as a red double arrow.
conformations of the isoleucine residue. Most rotamers inhibitor to bind with the optimal geometry and hydrogen
bonding pattern as observed for HA-1077 in PKA. Fur-of an isoleucine modeled into the Leu49 position in-
crease the number of interactions with the inhibitor or ther, the exchange Leu49Ile presumably optimizes the
van der Waals interactions—i.e., inhibitor fit—becausecause steric clashes with the inhibitor isoquinoline sul-
fonamide moiety. Because of the branching of the iso- of the position of the branch in the side chain. Whether
additional effects arise from the Val123Met exchangeleucine side chain at the C	, in contrast to a leucine
residue, the inhibitor binding pocket is narrowed in the remains to be seen. Last but not least, the AGC-kinase
typical Phe327 residue makes attractive contacts withexpected binding region of the isoquinoline methyl and
sulfonamide groups, also close to the Phe327 homolog; all inhibitors, but especially with the C22 extra methyl
group of H-1152P.this appears to favor H-1152P binding. It is likely that the
isoquinoline methyl group of H-1152P then additionally The higher affinity of Y-27632 for Rho-kinase is more
difficult to rationalize based on sequence considera-contributes to a productive interaction by a mutual in-
crease in the number of van der Waals interactions with tions. One determinant is probably the Leu49Ile ex-
change. The shorter branched methyl group is likely tothe isoleucine side chain.
How or even whether the Val123Met exchange might provide additional van der Waals interactions with three
different parts of the inhibitor molecule, thereby increas-affect binding selectivity is unclear. A relatively large
number of van der Waals contacts (Table 3) are formed ing the overall binding surface area and improving the
quality of the fit. The absence of steric clashes in theto all three inhibitors. A methionine residue is found at
this position in several kinases with known structures, region of Thr183 (and Glu127), however, obscures analy-
sis of possible contributions of the corresponding ex-including Erk, p38, Src, and Abl. In all these cases, the
methionine side chain is oriented away from the adeno- changes at these positions to the higher affinity of
Y-27632 in Rho-kinase. Regarding the Val123Met ex-sine subsite, providing little contact beyond the C

atom. By analogy, this methionine side chain therefore change, the likelihood that it is oriented away from the
inhibitor as discussed above leads to the conclusionis not likely to be a major factor in H-1152P specificity
for Rho-kinase. In addition, a large number of van der that Rho-specific interactions with the Met side chain
are possible but unlikely. A similar compound, Y-30141,Waals contacts are found with the residue Phe327,
which is conserved in most members of the AGC group which differs from Y-27632 by a pyrrolopyridine ring
replacing the pyridine ring, has a similar inhibitory pro-of protein kinases. Phe327 makes attractive additional
interactions with the isoquinoline extra methyl group of file, but a 10-fold higher affinity for Rho-kinases (Ishizaki
et al., 2000). Its selectivity, i.e., the ratios of the IC50 forH-1152P in PKA, compared to HA-1077.
Taken together, the higher affinities of HA-1077 and Rho-kinase to that for other kinases, however, is about
10-fold lower. In the binding pocket, the extra pyrrolidineH-1152P for Rho-kinase—and the especially strong
binding of the H-1152P derivative to Rho-kinase—can group is likely to make one additional hinge region con-
tact with its proton donor in the five ring, either to thebe explained largely by three factors: the Thr183Ala ex-
change and the concomitant relaxation of the steric carbonyl of Glu121 (PKA numbering) or, if rotated 80,
to the carbonyl of Val123. The higher affinity can alsoclash between the inhibitor C10 methyl group and
Thr183 and Leu173 (Figure 6). This in turn allows the be explained by the larger surface of the planar double
Crystal Structures of PKA with Rho-Kinase Inhibitors
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Table 5. Conservation of Residues in the Binding Pocket that Differ between PKA and Rho-Kinase
Rho
Residue in PKA PKA No.* % kinase No.* % Contact
49 Leu 241 49.1 Ile 186 37.9 side chain/backbone
51 Thr 18 3.7 Arg 71 14.5 backbone only
123 Val 76 15.5 Met 123 25.1 side chain/backbone
127 Glu 76 15.5 Asp 158 32.2 side chain
170 Glu 140 28.5 Asp 59 12.0 backbone only
183 Thr 76 15.5 Ala 142 28.9 side chain
Shown are residues in contact with the inhibitors that differ between PKA and Rho-kinase according to the alignment from www.kinase.com
(Manning et al., 2002). The total number of kinases in the alignment is 491. The number (No.*) as well as percentage (%) of kinases with the
same corresponding residue (numbering according to PKA) to PKA and Rho-kinase, respectively, were calculated. Contacts to the inhibitor
via main chain or side chain are indicated. Residues that have side chain contacts with the ATP-site ligands are in bold.
ring compared to the single ring of Y-27632. These addi- all kinase inhibitors cocrystallized with PKA so far. The
three inhibitors in this study make four (Y-27632), sixtional interactions can be assumed to increase the bind-
ing potency. The drop in selectivity can be explained if (HA-1077), or eight (H-1152P) van der Waals contacts
to Phe327. Sequence alignments of PKA versus ROCK-Ione assumes that the interactions which determine the
selectivity for these Y-class inhibitors remain the same or ROCK-II indicate that Rho-kinase also has a phenylal-
anine residue in a position homologous to Phe327 (Fig-for both inhibitors and thus are less relevant in the case
of the better binding Y-30141. ure 2). The crystal structure of AGC kinase PKB shows
residue Phe439 in a position identical to Phe327 in PKA
(Yang et al., 2002). More distantly related kinases, how-
Selectivity of the Inhibitors for Rho-Kinase
ever, do not have a corresponding C-terminal strand
Relative to Other Kinases
with a recognizably equivalent aromatic side chain (al-
We have argued above that many of the interactions
though other strands, domains, or subunits may contrib-
with residues which differ between Rho-kinase and PKA
ute a similar chain). Thus, the combination of all five
explain why HA-1077, H-1152P, and Y-27632 bind more
residues, Ile (Leu49), Ala (Thr183), Asp (Glu127), Met
tightly to Rho-kinase than to PKA. The amino acid resi-
(Val123), and Phe (Phe327), is an exclusive feature of
dues in question are, however, common in the kinase
Rho-kinase. It should be noted that these residues are
family. From the available kinetic data, at least HA-1077
also among the ones with the largest numbers of con-
and Y-27632 show selectivity for only a few kinases
tacts to the inhibitors, especially to H-1152P (Table 3).
(less data is available for H-1152P). The question arises
And, while the individual residues exchanges may be
whether selectivity arises from a unique combination of
relatively conserved, in combination they generate a
specific amino acid residues or simply from the sum of
uniquely shaped inhibitor binding pocket with unique
a small number of individual interactions that can be
electronic properties, rationalizing the selectivity of Rho-
considered independently of one another.
kinase for certain protein kinase inhibitors, such as HA-
Using a sequence alignment of 491 human kinases
1077, H-1152P, and Y-27632.
(see e.g., www.kinase.com; Manning et al., 2002), we
built a database to calculate the frequency of certain
amino acid residues and of their combinations. Table 5 Conclusions
The one common feature of all protein kinases is ATPshows the degree of conservation for the residues that
are different between PKA and Rho-kinase. Either iso- binding at a highly conserved ATP binding site with
highly conserved binding interactions. The highest de-leucine and leucine is found at the Leu49 position in
most kinases, with leucine more frequent than isoleu- gree of conservation is seen with the catalytic residues
that are absolutely conserved across the entire proteincine. Also, an alanine in the Thr183 position (28.9%) is
common (and more common than threonine with kinase family. The tertiary structure that forms the ATP
binding site is apparently highly conserved in the active15.5%). Relatively high frequencies are found also for
Rho-kinase side chains of methionine in the Val123 posi- state of the protein, but this conclusion depends upon
extrapolation from the still relatively few active struc-tion (25.1%) and aspartic acid at the Glu127 position
(32.2%). While these residues are common when con- tures that have been solved. The primary sequences are
mostly highly conserved at the residues that form thesidered individually, the combination of all four is nearly
unique. Only 6 out of 491 kinases possess the same triphosphoryl binding site, presumably because this rep-
resents the catalytic site. Conserved features of thecombination, 3 from the subgroup of cell cycle related
kinases (CRK7, CCRK, and CHED), and 3 tyrosine ki- adenosine binding site are restricted to the backbone
contacts of the hinge region and to a generally hy-nases, MUSK, MET and RON.
If we consider additionally the AGC characteristic resi- drophobic or aromatic environment surrounding ade-
nine; residues at positions homologous to Val57 anddue Phe327, the combination of inhibitor binding side
chains seen in Rho-kinase becomes truly unique. Ala70 in PKA are additionally conserved as small hy-
drophobic residues. Otherwise, there is considerablePhe327, located on a C-terminal strand that stretches
across the catalytic cleft, interacts with its aromatic side variability in sequence and, when considering inactive
forms, in structure among protein kinases. Physiologicalchain with the adenosine moiety of ATP, as well as with
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chip via amine group linkage was achieved using standard couplingroles for this variability are generally recognized only for
procedures (Lo¨fa˚s and Johnsson, 1990). Briefly, CM5 sensor chipsthose cases where specific events such as phosphoryla-
were activated by injecting 35 l of a 1:1 mixture of N-ethyl-N-tion are seen to modulate activity. Most protein kinases
[dimethylamino]carbodiimide/N-hydroxysuccinimide at 5 l/min.
bind ATP with low micromolar binding constants, con- After diluting the proteins in 10 mM sodium acetate (pH 5.5), PKA
sistent with the need for exchange of ATP, ADP, and (with HSA as a control) was coupled to the CM5 sensor chip by
injecting a 50 M solution of the protein selected with a flow rateunbound states. Thus, sequence and structural variabil-
of 5 l/min until 11,000 RU was reached.ity at the ATP binding pocket has few known physiologi-
cal roles regarding ATP binding, but is crucial for the
Generation of Kinetic Binding Dataselectivity of nonphysiological, high affinity ATP-site li-
Kinetic studies with a range of analyte concentrations were deter-gands, such as low molecular weight protein kinase
mined at a flow rate of 10 l/min by allowing 300 s for association
inhibitors. and 900 s for dissociation. Analytes were diluted in MilliQ water or
Crystallographic studies of enzyme-inhibitor complex running buffer (50 mM MOPS [pH 7.4], 50 mM KCl, and 10 mM
MgCl2). Kinetic data were analyzed with BIAevaluation 3.0 software.structures provide information directly relevant to the
For each binding curve, the response obtained using the HSA celldrug design tasks of optimizing potency and selectivity.
as control was subtracted. Due to the small signals (up to 40 RU),For protein kinases, these tasks are complicated by
the steady-state affinity model was used to determine the Ki ofseveral factors. First, the substrate binding sites are
the different small molecular weight compounds. Goodness of fit
relatively flexible, so that individual structures do not (measured as 2) was less than 5 for binding of the low molecular
fully characterize an enzyme. Secondly, as discussed weight compounds. All binding experiments were repeated two
times, and biosensor chips coupled at different times yielded sur-above, the natural substrates generally bind weakly, so
faces with identical binding affinities. The binding affinities ofthat tight binding inhibitors are not obviously derivable
H-1152P, HA-1077, and Y-27632 to PKA were similar to the Ki valuesfrom substrates. Third, the similarity of the ATP binding
reported in different studies (Sasaki et al., 2002; Uehata et al., 1997)sites of active protein kinases means that inhibitors are
and citations therein, using enzymatic assays.
likely to bind many of the ca. 600 kinases other than the
target kinase. Data Collection and Structure Determination
The development of potent and selective kinase inhib- Diffraction data were measured at 4C in a sealed capillary on an
image plate detector (Mar research) or Bruker X1000 area detectoritors and their success as therapeutics has demon-
using a copper target Rigaku Rotaflex X-ray generator and graphitestrated that problems anticipated with protein kinases
crystal K monochromator. In each case one crystal was sufficientas targets can be overcome. The process of optimization
to obtain a complete data set. The data were processed with theof such inhibitors can be improved. Of the inhibitors programs MOSFLM and SCALA or ASTRO and SAINT. All crystals
described here, only H-1152P was specifically designed have an orthorhombic symmetry (P212121) with similar cell constants
to target Rho-kinase. The crystal structures, however, (Table 1). The structures were determined by molecular replacement
using the CCP4 program package (www.ccp4.ac.uk/main/html). Asshow how they bind and identify the probable determi-
a starting model we chose a PKA structure in a closed conformationnants of Rho-kinase selectivity. This information focuses
(our unpublished data). Refmac 5.1.24 was used for refinement,strategies for chemical synthesis and should improve
while MOLOC was used (www.moloc.ch) for graphical evaluationthe overall efficiency in achieving desired inhibition pro- and model building.
files. Cocrystal structures of Rho-kinase with inhibitors
are needed to verify and possibly refine the model. Verifi- Surface Calculations
cation of the model would also verify the approach of Buried surfaces were calculated with the program Insight II (Accel-
rys). The total surface of the isolated inhibitor and the accessibleusing PKA as a surrogate for Rho-kinase crystallization,
surface of the inhibitor in the complex were calculated. The differ-which might remain a preferable approach if Rho-kinase
ence is the buried surface.crystallization proves difficult, or if only inactive confor-
mations of Rho-kinase will be crystallizable.
Sequence Alignment and Homology Model Building
Sequences were aligned using the ClustalW server from http://
Experimental Procedures
www.ebi.ac.uk/clustalw/. The homology model was calculated by
the SWISS-MODEL Protein Modelling Server (http://www.expasy.
Protein Expression and Purification
ch/swissmod/SWISS-MODEL.html).
Recombinant bovine C catalytic subunit of cAMP-dependent pro-
tein kinase (which differs from the human protein at two positions:
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